glp-1 receptor agonist examples Market Size & Analysis, 2026-2033 Research shows GLP-1 receptor agonist

Research goals: Metabolic & Weight Description Retatrutide (development code LY3437943) is a synthetic, once-weekly triple agonist of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors that has been the subject of peer-reviewed phase 1 and phase 2 randomized controlled trials published in The New England Journal of Medicine , The Lancet , and Nature Medicine , including investigations of body weight, glycemic control, and hepatic steatosis in adult human participants

Tesamorelin works upstream by improving growth hormone signaling

Wagner, D

Front Endocrinol (Lausanne) (2018) 9:124

Multiply by 100 for insulin syringe units